Pembrolizumab for treating resectable Stage II, IIIA, or IIIB (T3-4N2) non-small-cell lung cancer

Published on 17 Feb 2025
Last Updated on 4 Jun 2025

Guidance Recommendations

The Ministry of Health’s Drug Advisory Committee has not recommended pembrolizumab for inclusion on the MOH List of Subsidised Drugs, when used in combination with platinum-containing chemotherapy as neoadjuvant treatment, and then continued as monotherapy as adjuvant treatment after surgery, for the treatment of patients with resectable Stage II, IIIA, or IIIB (T3-4N2) non-small-cell lung cancer. The decision was based on the unfavourable cost-effectiveness of pembrolizumab compared with nivolumab, and an unacceptable pricing proposal from the company.

Clinical indication, subsidy class and MediShield Life claim limit for pembrolizumab are provided in the Annex.

Pembrolizumab for treating resectable Stage II, IIIA, or IIIB (T3-4N2) non-small-cell lung cancer (4 Jun 2025) [PDF, 218 KB]

PES Pembrolizumab for treating non-small-cell lung cancer before and after lung surgery (4 Jun 2025) [PDF, 61 KB]